ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 614,89
0,57%
Dow Jones
38 856,08
0,20%
DAX
18 105,89
0,18%
Brent Oil
84,305
0,48%
Bitcoin
64 738,09
-2,63%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Kintara Therapeutics Inc (KTRA)

  7. Kintara Therapeutics Inc (KTRA) Actualités

KTRA

Kintara Therapeutics (KTRA)

Kintara Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:KTRA
DateHeureSourceTitreSymboleSociété
13/06/202422h10Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:KTRAKintara Therapeutics Inc
13/06/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTRAKintara Therapeutics Inc
03/06/202414h35PR Newswire (US)TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)NASDAQ:KTRAKintara Therapeutics Inc
17/05/202422h10Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:KTRAKintara Therapeutics Inc
17/05/202422h05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:KTRAKintara Therapeutics Inc
14/05/202422h45PR Newswire (US)Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial ResultsNASDAQ:KTRAKintara Therapeutics Inc
14/05/202422h40Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KTRAKintara Therapeutics Inc
13/05/202422h06Edgar (US Regulatory)Form S-4 - Registration of securities, business combinationsNASDAQ:KTRAKintara Therapeutics Inc
05/04/202419h09PR Newswire (US)Kuehn Law Encourages KTRA, ABIO, SWAV, and NS Investors to Contact Law FirmNASDAQ:KTRAKintara Therapeutics Inc
03/04/202413h00PR Newswire (US)Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger AgreementNASDAQ:KTRAKintara Therapeutics Inc
27/03/202414h00PR Newswire (US)Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on PembrolizumabNASDAQ:KTRAKintara Therapeutics Inc
14/02/202422h07PR Newswire (US)Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate UpdateNASDAQ:KTRAKintara Therapeutics Inc
12/02/202415h00PR Newswire (US)Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast CancerNASDAQ:KTRAKintara Therapeutics Inc
18/12/202322h05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KTRAKintara Therapeutics Inc
07/12/202315h00PR Newswire (US)Kintara Therapeutics Announces Review of Strategic AlternativesNASDAQ:KTRAKintara Therapeutics Inc
05/12/202315h00PR Newswire (US)Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing RequirementNASDAQ:KTRAKintara Therapeutics Inc
13/11/202322h10PR Newswire (US)Kintara Therapeutics Announces Fiscal 2024 First Quarter Financial Results and Provides Corporate UpdateNASDAQ:KTRAKintara Therapeutics Inc
31/10/202313h00PR Newswire (US)Kintara Therapeutics Announces Preliminary Topline Results From GBM AGILE StudyNASDAQ:KTRAKintara Therapeutics Inc
27/10/202322h05Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:KTRAKintara Therapeutics Inc
04/10/202322h35Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:KTRAKintara Therapeutics Inc
21/09/202315h35GlobeNewswire Inc.Dawson James Securities Announces October Date for 8th Annual Small Cap Growth ConferenceNASDAQ:KTRAKintara Therapeutics Inc
18/09/202322h25Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:KTRAKintara Therapeutics Inc
02/09/202300h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTRAKintara Therapeutics Inc
01/09/202322h05Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:KTRAKintara Therapeutics Inc
15/06/202321h32Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KTRAKintara Therapeutics Inc
11/05/202314h02Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:KTRAKintara Therapeutics Inc
31/03/202322h17Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:KTRAKintara Therapeutics Inc
31/03/202322h15Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:KTRAKintara Therapeutics Inc
13/02/202322h30Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:KTRAKintara Therapeutics Inc
30/12/202222h58ValueWalkIs Kintara Therapeutics A Hidden Gem?NASDAQ:KTRAKintara Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KTRA

Dernières Valeurs Consultées

NASDAQ
AMZN
Amazon.com
EU
GLE
Societe Generale
EU
ORA
Orange
USI
USTECH100
US Tech 100
NYSE
KO
Coca Cola
NYSE
MCD
McDonalds
NASDAQ
AAPL
Apple
EU
EN
Bouygues
EU
PX1
CAC 40
EU
LR
Legrand
EU
CAP
Capgemini
EU
DG
Vinci
COIN
ETHUSD
Ethereum
SPI
SP500
S&P 500
EU
RNO
Renault
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés